Psychosocial Group Interventions for Depression: Systemic and Neurophysiological Correlates of Treatment Effect. A randomized, controlled trial (PsySysNe)
Major depression is a commonly occurring, recurrent disorder linked to diminished quality of life, medical morbidity, and mortality. The World Health Organization (WHO) has ranked depression the 4th leading cause of disability worldwide and estimates that by 2020, it will be the second leading cause. The most common options for depression treatment are medication and psychotheraphy, and their combined use has shown to provide the most efficient outcome. Although psychoteraphy would be beneficial to many patients and significantly increase the likelihood of recovery, there are not enough resources to offer needed treatment to all patients. It would be crucial to develop validated and efficacy tested group treatments to increase the number of patients within reach of appropriate treatment for depression. Cognitive behavioral analysis system of psychotherapy (CBASP) has been modified to be used for groups as a short 12 weeks intervention. Only one study has tested the efficacy of this treatment (Sayegh ym. 2012a), but it showed indication of positive effects. When implemented as individual therapy, CBASP has shown to be a promising treatment for depression, especially when combined with medication. In this project we aimed to test the efficacy of the 12-weeks group –versino of CBASP on depression symtoms and physioiogical markers. The changes where followed both in experienced symptoms (questionnaires), and in neurophysiological (and system level) markers of depression. The study was conducted as randomized controlled trials.
Project team
- Soili M. Lehto
- Sari Lindeman (KSSHP)
- Tiina Parviainen, CIBR (contact)
- Anu Ruusunen
- Hanna-Maija Lapinkero
- Reettakaisa Lehtinen
- Miila Salmi
- Kristiina Salmi
- Toni Hartikainen
- Rita Lehtinen
- Joanna Vacker
- Ainomaija Valkonen
- Katja Koskialho
Funding
- ERVA